-
Mashup Score: 2ESMO Immuno-Oncology Congress 2024: Registration - 2 hour(s) ago
Registration is open
Source: www.esmo.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6The 5th Annual OncoAlert Colloquium - 2 hour(s) ago
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Source: oncoalert.m-pages.comCategories: General Medicine News, Oncologists1Tweet-
The #OncoAlertColloquium 🚨Returns for its 5⃣th year The Year in Oncology 2024 with⚕️TOP Oncology Faculty and TOP Oncology Partners that will give this meeting a TRUE Interdisciplinary approach‼️ Registration is NOW OPEN LINK: https://t.co/IZgVZxwIYp See you soon! The Network… https://t.co/841qvpmNCz https://t.co/4Sz69h68aJ
-
-
Mashup Score: 0FCS - NUS CSI - 3 hour(s) ago
INFO AACR FCS SPEAKERS PROGRAM VENUE REGISTRATION ABSTRACTS ABOUT FCS SPONSORS ORGANIZERS Frontiers in Cancer Science 2024 Matrix, Biopolis 30 Biopolis Street, Singapore 138671 13-15 November 2024 | Singapore Frontiers … FCS Read More »
Source: csi.nus.edu.sgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
During IWWM-12, the Lymphoma Hub was pleased to speak to Christian Buske, Institute of Experimental Cancer Research, Ulm, DE. We asked about their highlights from IWWM-12 and the future perspectives shared at the workshop for the treatment of WM.
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Data from the INTERLACE trial shows induction chemotherapy followed by chemoradiotherapy prolongs overall survival in locally advanced cervical cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1OncLive’s October Roundup of Key FDA Approvals in Oncology - 3 hour(s) ago
Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Olaparib Without Androgen Deprivation for Biochemically Recurrent Prostate Cancer Following Prostatectomy - 4 hour(s) ago
This nonrandomized controlled trial aims to determine the activity of olaparib monotherapy among patients with high-risk biochemically recurrent prostate cancer after radical prostatectomy.
Source: jamanetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Effectively Targeting c-Met in Colorectal Cancer Is Becoming a Reality With Novel Approaches - 4 hour(s) ago
John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients? - 4 hour(s) ago
Nature Reviews Clinical Oncology – A number of therapeutics that target mediators of signalling in the hypothalamic and brainstem regions that control appetite, ingestive behaviour, satiety, nausea…
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Watch live to hear the latest current and emerging clinical data on the use of immunotherapy in patients with melanoma, hepatocellular carcinoma (HCC), and l…
Source: www.youtube.comCategories: General Medicine News, Oncologists1Tweet
#ESMOImmuno24: 🚨 Don’t miss out! Join us this December in Geneva to explore crucial aspects of immuno-oncology. Register by 13 November and save! #ImmunoOncology #Oncology #CancerResearch #Geneva #GlobalHealth 🔗 https://t.co/1uYTvveQdp https://t.co/beNlFx4xXz